We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

149 hedge funds and large institutions have $447M invested in Enanta Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 57 increasing their positions, 39 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 15

70.04% more ownership

Funds ownership: 0% → 70.04% (+70%)

46% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 39

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

29% more capital invested

Capital invested by funds: $347M → $447M (+$99.7M)

10% more funds holding

Funds holding: 136 → 149 (+13)

Holders
149
Holders Change
+13
Holders Change %
+9.56%
% of All Funds
3.73%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.1%
New
31
Increased
57
Reduced
39
Closed
15
Calls
$492K
Puts
–
Net Calls
+$492K
Net Calls Change
+$159K

Top Buyers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
+$8.92M
2
State Street
State Street
Massachusetts
+$6.79M
3
SCM
Stonepine Capital Management
Oregon
+$6.65M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$5.72M
5
BFA
BlackRock Fund Advisors
California
+$4.4M

Top Sellers

Rank Fund Capital Flow
1
SAM
Senzar Asset Management
New York
-$13.5M
2
GTC
Ghost Tree Capital
New York
-$6.65M
3
AL
AJO LP
Pennsylvania
-$5.9M
4
SIM
Spark Investment Management
New York
-$3.66M
5
Renaissance Technologies
Renaissance Technologies
New York
-$3.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
HA
26
Hays Advisory
Tennessee
$3.92M -$1.14M -39,608 -25%
MVM
27
McClain Value Management
Connecticut
$3.89M -$1.92M -66,933 -37%
AQR Capital Management
28
AQR Capital Management
Connecticut
$3.81M +$286K +9,977 +10%
Ameriprise
29
Ameriprise
Minnesota
$3.8M +$160K +5,570 +5%
NI
30
Numeric Investors
Massachusetts
$3.65M -$1.18M -41,100 -27%
Principal Financial Group
31
Principal Financial Group
Iowa
$3.44M +$38.6K +1,347 +1%
Two Sigma Investments
32
Two Sigma Investments
New York
$3.19M +$798K +27,848 +41%
Millennium Management
33
Millennium Management
New York
$3.17M -$1.93M -67,344 -42%
OM
34
Opaleye Management
Massachusetts
$3.02M +$2.58M +90,000 New
BIM
35
BlackRock Investment Management
Delaware
$2.85M +$356K +12,417 +17%
PNC Financial Services Group
36
PNC Financial Services Group
Pennsylvania
$2.82M +$1.99M +69,544 +473%
Goldman Sachs
37
Goldman Sachs
New York
$2.76M +$1.75M +61,136 +288%
QI
38
QS Investors
New York
$2.62M -$363K -12,675 -14%
GCP
39
GSA Capital Partners
United Kingdom
$2.59M -$127K -4,431 -5%
BBA
40
Baker Bros. Advisors
New York
$2.52M – – –
Deutsche Bank
41
Deutsche Bank
Germany
$2.16M -$3M -104,790 -62%
Invesco
42
Invesco
Georgia
$1.97M +$239K +8,333 +17%
USAA
43
United Services Automobile Association
Texas
$1.72M – – –
GAM
44
Gotham Asset Management
New York
$1.7M -$513K -17,885 -26%
Charles Schwab
45
Charles Schwab
California
$1.7M +$70.6K +2,464 +5%
Citigroup
46
Citigroup
New York
$1.69M +$941K +32,822 +186%
Morgan Stanley
47
Morgan Stanley
New York
$1.68M +$1.29M +45,008 +857%
Prudential Financial
48
Prudential Financial
New Jersey
$1.64M -$931K -32,476 -40%
TCIM
49
TIAA CREF Investment Management
New York
$1.59M -$451K -15,724 -25%
Wellington Management Group
50
Wellington Management Group
Massachusetts
$1.44M +$141K +4,921 +13%
1
2
3 4 5

ENTA Hedge Fund Activity: Q4 2016 in Review

149 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2016, worth a combined $447M — up 29% from $347M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ENTA positions and 15 closed out — a net gain of 16 holders — while 57 added to existing stakes and 39 trimmed.

The largest buyer was First Manhattan, adding an estimated $8.92M. The largest seller was Senzar Asset Management, exiting entirely with an estimated $13.5M sold.

  • 149 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2016, up from 136 in Q3 2016.
  • Funds reported $447M of Enanta Pharmaceuticals stock for Q4 2016, up 29% quarter-over-quarter.
  • 31 funds opened new Enanta Pharmaceuticals positions in Q4 2016 and 15 closed out, a net change of +16 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2016 was First Manhattan, an estimated $8.92M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2016 was Senzar Asset Management, an estimated $13.5M sold.

Based on aggregated 13F filings for Q4 2016.